Recovery and Biodistribution of Ex Vivo Expanded Human Erythroblasts Injected into NOD/SCID/IL2Rγnull mice. (16th August 2011)

• Record Type: Journal Article
• Authors: Ghinassi, Barbara; Ferro, Leda; Masiello, Francesca; Tirelli, Valentina; Sanchez, Massimo; Migliaccio, Giovanni; Whitsett, Carolyn; Kachala, Stefan; Riviere, Isabelle; Sadelain, Michel; Migliaccio, Anna Rita
• Other Names: Grazzini Giuliano Academic Editor.
• Is Part Of: Stem cells international. Volume 2011(2011)
• Publication Date: 2011-08-16
• Subjects: Stem Cells -- Periodicals; Stem Cells -- Therapeutic use -- Periodicals; Stem Cells -- Transplantation -- Periodicals; 616.0277405
• DOI: 10.4061/2011/673752
• Languages: English
• ISSNs: 1687-966X

Abstract

Abstract : Ex vivo expanded erythroblasts (EBs) may serve as advanced transfusion products provided that lodgment occurs in the macrophage-niche of the marrow permitting maturation. EBs expanded from adult and cord blood expressed the receptors (CXCR4, VLA-4, and P-selectin ligand 1) necessary for interaction with macrophages. However, 4-days following transfusion to intact NOD/SCID/IL2Rγ null mice, CD 235 a p o s EBs were observed insideCD 235 a n e g splenic cells suggesting that they underwent phagocytosis. When splenectomized and intact NOD/SCID/IL2Rγ null mice were transfused using retrovirally labeled human EBs, human cells were visualized by bioluminescence imaging only in splenectomized animals. Four days after injection, humanCD 235 a p o s cells were detected in marrow and liver of splenectomized mice but only in spleen of controls. HumanCD 235 a p o s erythrocytes in blood remained low in all cases. These studies establish splenectomized NOD/SCID/IL2Rγ null mice as a suitable model for tracking and quantification of human EBs in vivo .